Zyla Life Sciences SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction
Zyla Life Sciences reported SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction of -$26.06 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-14.
Discontinued › Notes › Valuation and Qualifying Accounts
us-gaap:ValuationAllowancesAndReservesDeductions · last filed 2020-05-14
- Zyla Life Sciences sec schedule, 12-09, valuation allowances and reserves, deduction for the quarter ending 2020-03-31 was -$26.06M.
- Zyla Life Sciences sec schedule, 12-09, valuation allowances and reserves, deduction for the quarter ending 2018-12-31 was -$25.62M.
- Zyla Life Sciences sec schedule, 12-09, valuation allowances and reserves, deduction for the quarter ending 2018-09-30 was -$21.07M.
- Zyla Life Sciences sec schedule, 12-09, valuation allowances and reserves, deduction for the quarter ending 2018-06-30 was -$18.89M.
- Zyla Life Sciences sec schedule, 12-09, valuation allowances and reserves, deduction for fiscal 2018 was -$75.14M.
| Period end | SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction 1 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction 2 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction 3 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction 5 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction 6 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction 8 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction 9 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction 11 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction 12 month |
|---|---|---|---|---|---|---|---|---|---|
| 2020-03-31 | -$26.06M 10-Q · filed 2020-05-14 | ||||||||
| 2019-12-31 | -$176.74M 10-K · filed 2020-03-26 | ||||||||
| 2019-09-30 | -$124.45M 10-Q · filed 2019-11-14 | ||||||||
| 2019-06-30 | -$66.53M 10-Q · filed 2019-08-13 | ||||||||
| 2019-03-31 | -$25.41M 10-Q · filed 2020-05-14 | ||||||||
| 2019-01-31 | -$64.00K 10-Q · filed 2020-05-14 | ||||||||
| 2018-12-31 | -$25.62M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | -$46.69M derived: sum of 2 quarters · filed 2020-03-26 | -$65.58M derived: sum of 3 quarters · filed 2020-03-26 | -$75.14M 10-K · filed 2020-03-26 | |||||
| 2018-09-30 | -$21.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$39.96M derived: sum of 2 quarters · filed 2019-11-14 | -$49.52M 10-Q · filed 2019-11-14 | ||||||
| 2018-06-30 | -$18.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$28.45M 10-Q · filed 2018-08-09 | |||||||
| 2018-03-31 | -$9.56M 10-Q · filed 2018-05-10 |